gip glp 1 dual agonist Targeting GLP-1, & GCG in Obesity and Type 2 Diabetes Research GI Adverse Effects of Glucagon-Like
Description
Compared with SGLT-2 inhibitors, the GLP-1 receptor agonist-SGLT-2 inhibitor combination was associated with a 29% lower risk of major adverse cardiovascular events (7.6 v 10.7 events per 1000 person years
Looking forward, the horizon seems promising for GLP-1 agonists, with new formulations and combination therapies under investigation
doi: 10.1038/nm.3761 [DOI] [PubMed] [Google Scholar] 79
Mean weight reductions corresponding to each group are 4.1%, 5.3%, 7.1%, 2.7%, and 1.4%, respectively (90)
Please wait
